China Biologic Products Holdings, Inc. logo
China Biologic Products Holdings, Inc. CBPO

China Biologic Products Holdings, Inc. Long-Term Debt 2011-2026 | CBPO

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:
  • Term exceeds 12 months
  • Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
  • Repaid through regular payments (interest and/or principal) over several years
Why long-term debt is needed:
  • Investment in development
    Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
  • Smoothing of cash flows
    A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
  • Optimization of capital structure
    A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:
  • Mortgage loans for property purchases
  • Corporate bonds issued by a company to raise capital
  • Project financing — long-term loans for building or expanding production facilities
  • Leasing obligations for equipment or transport

Annual Long-Term Debt China Biologic Products Holdings, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - 40 M 30 M - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
40 M 30 M 35 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer Long-Term Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
273 M - 2.43 % $ 254 M germanyGermany
Cerus Corporation Cerus Corporation
CERS
10.2 M $ 2.61 28.62 % $ 497 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
2.95 M - -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
231 M $ 97.03 -6.21 % $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
68.2 M - - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
529 K - - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
4.76 M - -18.52 % $ 27.3 M britainBritain
AlloVir AlloVir
ALVR
1.13 M - 4.14 % $ 49.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
2.42 B - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
1.83 M - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
173 M - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
42 M $ 21.91 -2.41 % $ 3.63 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
278 K - -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
338 K - - $ 269 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
49 K - - $ 10.1 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
1.33 M - - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
17.5 B - - $ 96.9 B britainBritain
Atreca Atreca
BCEL
60.3 M - -11.76 % $ 5.79 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
102 K $ 1.72 -0.87 % $ 115 M usaUSA
Berkeley Lights Berkeley Lights
BLI
22.7 M - -7.31 % $ 87 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
1.67 M - -10.95 % $ 876 K usaUSA
Advaxis Advaxis
ADXS
8.14 M - -9.65 % $ 45.9 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
467 K - - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
4.72 M - - $ 3.74 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
175 M - - - russiaRussia
Caladrius Biosciences Caladrius Biosciences
CLBS
137 K - -16.75 % $ 25.8 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
31 K - 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
171 K - -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
4 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
9.12 M - - $ 26.5 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
22.4 M - - $ 2.18 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
2.29 M - 1.93 % $ 17.4 M usaUSA
Editas Medicine Editas Medicine
EDIT
53.6 M $ 2.91 -3.0 % $ 258 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
19.8 K $ 17.35 -5.06 % $ 55.5 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
26.4 M - - $ 2.02 B usaUSA
Akouos Akouos
AKUS
28.3 M - 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
38.2 M - - $ 28.6 M usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
39.6 M - -9.21 % $ 2.55 M usaUSA
Eloxx Pharmaceuticals Eloxx Pharmaceuticals
ELOX
8.56 M - -5.68 % $ 8.28 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
25.4 M - - $ 867 M germanyGermany
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
274 K - -11.43 % $ 502 K usaUSA
Applied Therapeutics Applied Therapeutics
APLT
38 K - - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
193 K - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
22.1 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
1.88 M - -13.39 % $ 1.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
1.82 M $ 0.57 0.07 % $ 2.46 M israelIsrael